AU2012335009B2 - Calcimimetics and methods for their use - Google Patents

Calcimimetics and methods for their use Download PDF

Info

Publication number
AU2012335009B2
AU2012335009B2 AU2012335009A AU2012335009A AU2012335009B2 AU 2012335009 B2 AU2012335009 B2 AU 2012335009B2 AU 2012335009 A AU2012335009 A AU 2012335009A AU 2012335009 A AU2012335009 A AU 2012335009A AU 2012335009 B2 AU2012335009 B2 AU 2012335009B2
Authority
AU
Australia
Prior art keywords
seq
calcimimetic
pth
dose
arrrar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012335009A
Other languages
English (en)
Other versions
AU2012335009A1 (en
Inventor
Gregory Bell
James E. Tomlinson
Sarah Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kai Pharmaceuticals Inc
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47258113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012335009(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of AU2012335009A1 publication Critical patent/AU2012335009A1/en
Application granted granted Critical
Publication of AU2012335009B2 publication Critical patent/AU2012335009B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012335009A 2011-11-10 2012-11-12 Calcimimetics and methods for their use Active AU2012335009B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558389P 2011-11-10 2011-11-10
US61/558,389 2011-11-10
PCT/US2012/064717 WO2013071262A1 (en) 2011-11-10 2012-11-12 Calcimimetics and methods for their use

Publications (2)

Publication Number Publication Date
AU2012335009A1 AU2012335009A1 (en) 2014-05-29
AU2012335009B2 true AU2012335009B2 (en) 2017-08-31

Family

ID=47258113

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012335009A Active AU2012335009B2 (en) 2011-11-10 2012-11-12 Calcimimetics and methods for their use

Country Status (9)

Country Link
US (3) US20140315809A1 (enExample)
EP (1) EP2776129B2 (enExample)
JP (2) JP6204369B2 (enExample)
CN (2) CN109985228A (enExample)
AU (1) AU2012335009B2 (enExample)
CA (1) CA2854911C (enExample)
HK (1) HK1202086A1 (enExample)
MX (1) MX355063B (enExample)
WO (1) WO2013071262A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
JP5270799B2 (ja) 2009-07-29 2013-08-21 カイ・ファーマシューティカルズ・インコーポレイテッド 副甲状腺ホルモンを低減する治療剤
CN114376970A (zh) 2013-06-28 2022-04-22 美国安进公司 Etelcalcetide (AMG 416)的稳定的液体制剂
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
TW201615195A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 阿那格雷藥物應用於癌症治療
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
CN106928320B (zh) 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
US11450405B2 (en) * 2018-10-18 2022-09-20 Fresenius Medical Care Holdings, Inc. Techniques for modeling parathyroid gland functionality and calcimimetic drug activity
US12433938B2 (en) 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN114222578B (zh) * 2019-12-09 2024-06-25 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
EP4212542A4 (en) * 2020-09-10 2024-08-28 Shaanxi Micot Technology Co., Ltd. BISPECIFIC FUSION POLYPEPTIDE COMPOUND
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
TW202313655A (zh) * 2021-06-08 2023-04-01 大陸商北京拓界生物醫藥科技有限公司 鈣敏感受體激動劑化合物的鹽酸鹽及醫藥組成物和其應用
US20240269227A1 (en) * 2021-06-08 2024-08-15 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Calcium-sensing receptor agonist composition and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028394A1 (en) * 2009-07-29 2011-02-03 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO1998004591A1 (en) * 1996-07-31 1998-02-05 The General Hospital Corporation Novel parathyroid hormone-related peptide analogs
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
IL153378A0 (en) 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
US6998404B2 (en) * 2001-08-08 2006-02-14 Genomed, Llc Treatment or prevention of acute renal failure
AU2006227429A1 (en) * 2005-03-17 2006-09-28 Amgen Inc. Methods of decreasing calcification
CA2669914C (en) 2006-11-16 2017-11-07 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
US20080261926A1 (en) * 2007-04-02 2008-10-23 Liu Julie F Pharmaceutical Calcimimetics
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028394A1 (en) * 2009-07-29 2011-02-03 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SOUQIYYEH M.Z. et al., "Survey of Attitudes of Physicians toward the Current Evaluation and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)", Saudi J. Kidney. Dis. Transpl., 2010, Vol. 21, No. 1, pages 93-101 *
SVARA F., "Chronic kidney disease - mineral and bone disorder (CKD-MBD): a new term for a complex approach", Journal of Renal Care, 2009, Vol. 35, Supplement 1, pages 3-6 *

Also Published As

Publication number Publication date
MX2014005662A (es) 2014-11-10
AU2012335009A1 (en) 2014-05-29
CA2854911C (en) 2019-09-24
US20160175383A1 (en) 2016-06-23
US20140315809A1 (en) 2014-10-23
HK1202086A1 (en) 2015-09-18
EP2776129B2 (en) 2020-06-17
WO2013071262A1 (en) 2013-05-16
US20170252397A1 (en) 2017-09-07
EP2776129A1 (en) 2014-09-17
JP2015502346A (ja) 2015-01-22
JP2017160269A (ja) 2017-09-14
MX355063B (es) 2018-04-04
JP6204369B2 (ja) 2017-09-27
CN109985228A (zh) 2019-07-09
CN104168955A (zh) 2014-11-26
EP2776129B1 (en) 2017-03-29
CA2854911A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
AU2012335009B2 (en) Calcimimetics and methods for their use
US20250163103A1 (en) Therapeutic agents for reducing parathyroid hormone levels
HK1241270A1 (en) Therapeutic agents for reducing parathyroid hormone levels
HK1241270B (en) Therapeutic agents for reducing parathyroid hormone levels
HK1167108B (en) Therapeutic agents for reducing parathyroid hormone levels

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)